collection
MENU ▼
Read by QxMD icon Read
search

ALL

shared collection
38 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28760298/minimal-residual-disease-assessment-and-risk-based-therapy-in-acute-lymphoblastic-leukemia
#1
REVIEW
Renato Bassan, Tamara Intermesoli, Annamaria Scattolin, Piera Viero, Elena Maino, Rosaria Sancetta, Francesca Carobolante, Francesca Gianni, Paola Stefanoni, Manuela Tosi, Orietta Spinelli, Alessandro Rambaldi
The study of minimal residual disease (MRD) in adult patients with acute lymphoblastic leukemia (ALL) allows a greater refinement of the individual risk classification and is the best support for risk-specific therapy with or without allogeneic hematopoietic cell transplantation (HCT). Using case-specific sensitive molecular probes or multiparametric flow cytometry on marrow samples obtained from the end of induction until midconsolidation, MRD assays can detect up to 1 leukemic cell of 10,000 total mononuclear cells (sensitivity, 0...
July 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28665419/acute-lymphoblastic-leukemia-a-comprehensive-review-and-2017-update
#2
REVIEW
T Terwilliger, M Abdul-Hay
Acute lymphoblastic leukemia (ALL) is the second most common acute leukemia in adults, with an incidence of over 6500 cases per year in the United States alone. The hallmark of ALL is chromosomal abnormalities and genetic alterations involved in differentiation and proliferation of lymphoid precursor cells. In adults, 75% of cases develop from precursors of the B-cell lineage, with the remainder of cases consisting of malignant T-cell precursors. Traditionally, risk stratification has been based on clinical factors such age, white blood cell count and response to chemotherapy; however, the identification of recurrent genetic alterations has helped refine individual prognosis and guide management...
June 30, 2017: Blood Cancer Journal
https://www.readbyqxmd.com/read/18285545/risk-adjusted-therapy-of-acute-lymphoblastic-leukemia-can-decrease-treatment-burden-and-improve-survival-treatment-results-of-2169-unselected-pediatric-and-adolescent-patients-enrolled-in-the-trial-all-bfm-95
#3
RANDOMIZED CONTROLLED TRIAL
Anja Möricke, Alfred Reiter, Martin Zimmermann, Helmut Gadner, Martin Stanulla, Michael Dördelmann, Lutz Löning, Rita Beier, Wolf-Dieter Ludwig, Richard Ratei, Jochen Harbott, Joachim Boos, Georg Mann, Felix Niggli, Andreas Feldges, Günter Henze, Karl Welte, Jörn-Dirk Beck, Thomas Klingebiel, Charlotte Niemeyer, Felix Zintl, Udo Bode, Christian Urban, Helmut Wehinger, Dietrich Niethammer, Hansjörg Riehm, Martin Schrappe
The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed to reduce acute and long-term toxicity in selected patient groups with favorable prognosis and to improve outcome in poor-risk groups by treatment intensification. These aims were pursued through a stratification strategy using white blood cell count, age, immunophenotype, treatment response, and unfavorable genetic aberrations providing an excellent discrimination of risk groups. Estimated 6-year event-free survival (6y-pEFS) for all 2169 patients was 79...
May 1, 2008: Blood
https://www.readbyqxmd.com/read/25962869/differences-in-childhood-leukemia-incidence-and-survival-between-southern-thailand-and-the-united-states-a-population-based-analysis
#4
COMPARATIVE STUDY
Kathryn Demanelis, Hutcha Sriplung, Rafael Meza, Surapon Wiangnon, Laura S Rozek, Michael E Scheurer, Philip J Lupo
BACKGROUND: Childhood leukemia incidence and survival varies globally, and this variation may be attributed to environmental risk factors, genetics, and/or disparities in diagnosis and treatment. PROCEDURE: We analyzed childhood leukemia incidence and survival trends in children aged 0-19 years from 1990 to 2011 in Songkhla, Thailand (n = 316) and compared these results to US data from the Surveillance, Epidemiology, and End Results (SEER) registry (n = 6,738). We computed relative survival using Ederer II and estimated survival functions using the Kaplan-Meier method...
October 2015: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/26069331/time-to-tune-the-treatment-of-ph-all
#5
COMMENT
Masamitsu Yanada
In this issue of Blood, Chalandon et al report the results of a prospective randomized study comparing standard vs less-intensive chemotherapy, both combined with imatinib, for patients with newly diagnosed Philadelphia chromosome–positive (Ph+) acute lymphoblastic leukemia (ALL). They show that the less-intensive therapy reduces early mortality without impairing efficacy, resulting in a significantly higher hematologic complete remission (CR) rate and an equivalent major molecular response (MMolR) rate.
June 11, 2015: Blood
https://www.readbyqxmd.com/read/22727007/distant-testing-in-laboratory-hematology-and-flow-cytometry-the-indian-experience
#6
REVIEW
Amar Das Gupta
Outsourcing or sending out of patients' samples to other laboratories for hematologic investigations is a common practice these days. Preanalytic variables that alter cellular parameters and levels of analytes in transit and on storage can significantly and adversely affect interpretation of test results in hematology. Awareness of these changes is necessary to avoid misinterpretation of results that in turn could influence medical management decisions.
June 2012: Clinics in Laboratory Medicine
https://www.readbyqxmd.com/read/24022849/validation-of-cell-based-fluorescence-assays-practice-guidelines-from-the-international-council-for-standardization-of-haematology-and-international-clinical-cytometry-society
#7
(no author information available yet)
No abstract text is available yet for this article.
September 2013: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/18752282/miflowcyt-the-minimum-information-about-a-flow-cytometry-experiment
#8
Jamie A Lee, Josef Spidlen, Keith Boyce, Jennifer Cai, Nicholas Crosbie, Mark Dalphin, Jeff Furlong, Maura Gasparetto, Michael Goldberg, Elizabeth M Goralczyk, Bill Hyun, Kirstin Jansen, Tobias Kollmann, Megan Kong, Robert Leif, Shannon McWeeney, Thomas D Moloshok, Wayne Moore, Garry Nolan, John Nolan, Janko Nikolich-Zugich, David Parrish, Barclay Purcell, Yu Qian, Biruntha Selvaraj, Clayton Smith, Olga Tchuvatkina, Anne Wertheimer, Peter Wilkinson, Christopher Wilson, James Wood, Robert Zigon, Richard H Scheuermann, Ryan R Brinkman
A fundamental tenet of scientific research is that published results are open to independent validation and refutation. Minimum data standards aid data providers, users, and publishers by providing a specification of what is required to unambiguously interpret experimental findings. Here, we present the Minimum Information about a Flow Cytometry Experiment (MIFlowCyt) standard, stating the minimum information required to report flow cytometry (FCM) experiments. We brought together a cross-disciplinary international collaborative group of bioinformaticians, computational statisticians, software developers, instrument manufacturers, and clinical and basic research scientists to develop the standard...
October 2008: Cytometry. Part A: the Journal of the International Society for Analytical Cytology
https://www.readbyqxmd.com/read/23943573/flow-cytometry-in-hematological-disorders
#9
REVIEW
Hara Prasad Pati, Sonal Jain
Flow cytometry with its rapidly increasing applications is being used essentially in all fields of diagnostic medicine. In hematological disorders it is most commonly used in diagnosis, characterization, prognostication and even selecting target therapy of acute leukemia and to some extent lymphomas. It is increasingly finding place in other fields of hematology i.e., non-malignant disorders of all blood cell types including RBCs and platelets along with leukocytes. In this review the authors have discussed some of these applications with an emphasis on disorders specific to pediatric patients...
September 2013: Indian Journal of Pediatrics
https://www.readbyqxmd.com/read/24811935/a-quality-improvement-assessment-of-multiple-concurrent-flow-cytometry-analyses-at-a-tertiary-care-center
#10
H E Karnes, J L Frater
INTRODUCTION: The utility of flow cytometry (FC) in diagnosis and staging of hematologic malignancy is controversial. Often, multiple specimens from the same patient are processed concurrently for FC analyses, alongside tissue for histomorphologic diagnosis. METHODS: To assess the diagnostic utility of multiple, concurrent FC analyses, a 10-year retrospective review of cases with ≥2 concurrent specimens (from the same patient) submitted for FC was conducted. Light microscopic (LM) diagnoses were compared to FC findings, and the contribution of FC results to final diagnoses was examined...
February 2015: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/24134778/sensitivity-and-specificity-of-cerebrospinal-fluid-flow-cytometry-for-the-diagnosis-of-leukemic-meningitis-in-acute-lymphoblastic-leukemia-lymphoma
#11
Zahi Mitri, Momin T Siddiqui, Fuad El Rassi, Jeannine T Holden, Leonard T Heffner, Amelia Langston, Edmund K Waller, Elliott Winton, Morgan McLemore, Leon Bernal-Mizrachi, David Jaye, Martha Arellano, Hanna Jean Khoury
The presence of leukemic blasts detected by light microscopy in cerebrospinal fluid (CSF) establishes the diagnosis of leukemic meningitis in acute lymphoblastic leukemia/lymphoma (ALL). Flow cytometry immunophenotyping (FCI) is a very sensitive method that detects a minute number of aberrant cells, and is increasingly performed on CSF samples. We sought to determine the sensitivity and specificity of CSF FCI for the diagnosis of leukemic meningitis in ALL. Between November 2007 and August 2011, 800 CSF samples from 80 patients with ALL were available from diagnostic lumbar punctures (LPs; n = 80), follow-up LPs (n = 687) and at the time of relapse (n = 33)...
July 2014: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/25906832/principles-of-minimal-residual-disease-detection-for-hematopoietic-neoplasms-by-flow-cytometry
#12
REVIEW
Brent L Wood
Flow cytometry has become an indispensible tool for the diagnosis and classification of hematopoietic neoplasms. The ability to rapidly distinguish cellular subpopulations via multiparametric assessment of quantitative differences in antigen expression on single cells and enumerate the relative sizes of the resulting subpopulations is a key feature of the technology. More recently, these capabilities have been expanded to include the identification and enumeration of rare subpopulations within complex cellular mixtures, for example, blood or bone marrow, leading to the application for post-therapeutic monitoring or minimal residual disease detection...
January 2016: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/25270227/methodological-aspects-of-minimal-residual-disease-assessment-by-flow-cytometry-in-acute-lymphoblastic-leukemia-a-french-multicenter-study
#13
C Fossat, M Roussel, I Arnoux, V Asnafi, C Brouzes, F Garnache-Ottou, M C Jacob, E Kuhlein, E Macintyre-Davi, A Plesa, N Robillard, J Tkaczuk, N Ifrah, H Dombret, M C Béné, A Baruchel, R Garand
Background: Minimal residual disease (MRD) assessment provides a powerful prognostic factor for therapeutic stratification in acute lymphoblastic leukemia (ALL). Multiparameter flow cytometry (MFC) has the potential for a rapid and sensitive identification of high risk patients. Our group has previously published that MRD levels analyzed by clone specific Ig/TcR-QPCR and MFC were concordant at a sensitivity of 10(-4) . Here we report the MFC methodological aspects from this multi-center experience. Methods: MRD was assessed by MFC in 1030 follow-up samples from 265 pediatric and adult patients with de novo ALL treated in the FRALLE, EORTC or GRALL clinical trials...
October 1, 2014: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/24700616/-first-proposed-panels-on-acute-leukemia-for-four-color-immunophenotyping-by-flow-cytometry-from-the-brazilian-group-of-flow-cytometry-gbcflux
#14
Maura R V Ikoma, Alex F Sandes, Leandro S Thiago, Geraldo B Cavalcanti Júnior, Irene G H Lorand-Metze, Elaine S Costa, Glicinia Pimenta, Maria C Santos-Silva, Nydia S Bacal, Mihoko Yamamoto, Elizabeth X Souto
Multiparameter flow cytometry (MFC) is a highly sensitive, fast and specific diagnostic technology with a wide range of applicability in hematology. Although well-established eight-color immunophenotyping panels are already available, most Brazilian clinical laboratories are equipped with four-color flow cytometer facilities. Based on this fact, the Brazilian Group of Flow Cytometry (Grupo Brasileiro de Citometria de Fluxo, GBCFLUX) for standardization of clinical flow cytometry has proposed an antibody panel designed to allow precise diagnosis and characterization of acute leukemia (AL) within resource-restricted areas...
April 4, 2014: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/24753208/first-proposed-panels-on-acute-leukemia-for-four-color-immunophenotyping-by-flow-cytometry-from-the-brazilian-group-of-flow-cytometry-gbcflux
#15
Maura R V Ikoma, Alex F Sandes, Leandro S Thiago, Geraldo B Cavalcanti Júnior, Irene G H Lorand-Metze, Elaine S Costa, Glicinia Pimenta, Maria C Santos-Silva, Nydia S Bacal, Mihoko Yamamoto, Elizabeth X Souto
Multiparameter flow cytometry is a highly sensitive, fast, and specific diagnostic technology with a wide range of applicability in hematology. Although well-established eight-color immunophenotyping panels are already available, most Brazilian clinical laboratories are equipped with four-color flow cytometer facilities. Based on this fact, the Brazilian Group of Flow Cytometry (Grupo Brasileiro de Citometria de Fluxo, GBCFLUX) for standardization of clinical flow cytometry has proposed an antibody panel designed to allow precise diagnosis and characterization of acute leukemia (AL) within resource-restricted areas...
May 2015: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/24752047/treatment-of-high-risk-philadelphia-chromosome-negative-acute-lymphoblastic-leukemia-in-adolescents-and-adults-according-to-early-cytologic-response-and-minimal-residual-disease-after-consolidation-assessed-by-flow-cytometry-final-results-of-the-pethema-all
#16
MULTICENTER STUDY
Josep-Maria Ribera, Albert Oriol, Mireia Morgades, Pau Montesinos, Josep Sarrà, José González-Campos, Salut Brunet, Mar Tormo, Pascual Fernández-Abellán, Ramon Guàrdia, María-Teresa Bernal, Jordi Esteve, Pere Barba, María-José Moreno, Arancha Bermúdez, Antonia Cladera, Lourdes Escoda, Raimundo García-Boyero, Eloy Del Potro, Juan Bergua, María-Luz Amigo, Carlos Grande, María-José Rabuñal, Jesús-María Hernández-Rivas, Evarist Feliu
PURPOSE: Minimal residual disease (MRD) is an important prognostic factor in adults with acute lymphoblastic leukemia (ALL) and may be used for treatment decisions. The Programa Español de Tratamientos en Hematología (PETHEMA) ALL-AR-03 trial (Treatment of High Risk Adult Acute Lymphoblastic Leukemia [LAL-AR/2003]) assigned adolescent and adult patients (age 15 to 60 years) with high-risk ALL (HR-ALL) without the Philadelphia (Ph) chromosome to chemotherapy or to allogeneic hematopoietic stem-cell transplantation (allo-HSCT) according to early cytologic response (day 14) and flow-MRD level after consolidation...
May 20, 2014: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/25693572/cytometry-measure-for-measure
#17
Jim Kling
No abstract text is available yet for this article.
February 19, 2015: Nature
https://www.readbyqxmd.com/read/22997141/ikaros-ikzf1-alterations-and-minimal-residual-disease-at-day-15-assessed-by-flow-cytometry-predict-prognosis-of-childhood-bcr-abl-negative-acute-lymphoblastic-leukemia
#18
Jana Volejnikova, Ester Mejstrikova, Petra Dörge, Barbara Meissner, Olga Zimmermannova, Karel Svojgr, Martin Stanulla, Gunnar Cario, Martin Schrappe, Jan Stary, Ondrej Hrusak, Jan Trka, Eva Fronkova
BACKGROUND: Recently, several studies have demonstrated a negative prognostic impact of Ikaros (IKZF1) gene alterations in acute lymphoblastic leukemia (ALL). However, controversies still exist regarding the impact of IKZF1 in current treatment protocols. PROCEDURE: We simultaneously detected IKZF1 gene deletions by multiplex ligation-dependent probe amplification and gene expression of IKZF1 isoforms in 206 children with BCR/ABL-negative ALL treated with ALL IC-BFM 2002 protocol, in which risk stratification was not based on minimal residual disease (MRD), and validated the results on a cohort of 189 patients treated with MRD-directed ALL-BFM 2000 protocol...
March 2013: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/23590661/technical-issues-flow-cytometry-and-rare-event-analysis
#19
REVIEW
B D Hedley, M Keeney
Flow cytometry has become an essential tool for identification and characterization of hematological cancers and now, due to technological improvements, allows the identification and rapid enumeration of small tumor populations that may be present after induction therapy (minimal residual disease, MRD). The quantitation of MRD has been shown to correlate with relapse and survival rates in numerous diseases and in certain cases, and evidence of MRD is used to alter treatment protocols. Recent improvements in hardware allow for high data rate collection...
June 2013: International Journal of Laboratory Hematology
https://www.readbyqxmd.com/read/20506466/refining-the-white-blood-cell-differential-the-first-flow-cytometry-routine-application
#20
Mikael Roussel, Cyrille Benard, Beatrice Ly-Sunnaram, Thierry Fest
A Complete Blood Count performed by an automated hematology analyzer frequently needs a microscopic slide review. This step is time consuming and requires experienced personnel. Recently, several teams have proposed and validated convenient combinations of monoclonal antibodies for an extended white blood cell (WBC) differential by flow cytometry. The aim of this study was to evaluate the usefulness of this approach in the routine workflow of a hematology laboratory. We compared a workflow chain comprised of a robotic blood preparation system (for antibody labeling), a flow cytometer, and data management software to the standard manual review of a blood film and evaluated the diagnostic quality, the turnaround time, and the labor needed for the two different approaches...
June 2010: Cytometry. Part A: the Journal of the International Society for Analytical Cytology
label_collection
label_collection
4584
1
2
2015-06-02 19:16:29
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"